Lombard Medical Inc. (NASDAQ:EVAR) has been assigned an average broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation. Lombard Medical’s rating score has declined by 50% in the last 90 days as a result of various analysts’ upgrades and downgrades.

Analysts have set a 12 month consensus price target of $1.75 for the company and are forecasting that the company will post ($0.26) EPS for the current quarter, according to Zacks. Zacks has also assigned Lombard Medical an industry rank of 105 out of 265 based on the ratings given to its competitors.

A number of equities research analysts have recently weighed in on the stock. Barclays PLC lowered their price objective on shares of Lombard Medical from $2.50 to $1.00 and set an “equal weight” rating for the company in a report on Tuesday, August 23rd. BTIG Research reaffirmed a “hold” rating on shares of Lombard Medical in a research note on Tuesday, August 23rd.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/18/zacks-lombard-medical-inc-evar-receives-consensus-rating-of-hold-from-brokerages.html

Lombard Medical (NASDAQ:EVAR) traded down 7.500% on Tuesday, hitting $0.851. 7,352 shares of the company’s stock were exchanged. The stock’s market cap is $16.85 million. The firm has a 50 day moving average price of $0.90 and a 200-day moving average price of $1.20. Lombard Medical has a 52-week low of $0.55 and a 52-week high of $3.96.

Lombard Medical (NASDAQ:EVAR) last announced its quarterly earnings data on Monday, August 22nd. The company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.40) by $0.02. The business earned $3.80 million during the quarter, compared to the consensus estimate of $3.78 million. Lombard Medical had a negative return on equity of 91.24% and a negative net margin of 258.98%. The company’s revenue was down 16.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.51) earnings per share. Analysts predict that Lombard Medical will post ($1.31) earnings per share for the current fiscal year.

About Lombard Medical

Lombard Medical, Inc is a medical technology company. The Company specializes in developing, manufacturing, and marketing endovascular stent-grafts for repair of aortic aneurysms. Its lead product, Aorfix, is an abdominal aortic aneurysm (AAA) stent-graft for the treatment of AAAs with angulation at the neck of the aneurysm of up to 90 degrees.

5 Day Chart for NASDAQ:EVAR

Get a free copy of the Zacks research report on Lombard Medical (EVAR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Lombard Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lombard Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.